このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Quantum Genomics Société Anonyme 将来の成長

Future 基準チェック /06

現在、 Quantum Genomics Société Anonymeの成長と収益を予測するのに十分なアナリストの調査がありません。

主要情報

n/a

収益成長率

n/a

EPS成長率

Biotechs 収益成長	10.5%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	01 Dec 2023

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

ENXTPA:ALQGC - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2024	N/A	-3	-3	N/A	1
12/31/2023	0	-3	N/A	N/A	N/A
9/30/2023	0	-11	N/A	N/A	N/A
6/30/2023	0	-18	-17	-17	N/A
3/31/2023	1	-22	-18	-18	N/A
12/31/2022	3	-25	-20	-20	N/A
9/30/2022	3	-22	N/A	N/A	N/A
6/30/2022	5	-20	-23	-23	N/A
3/31/2022	5	-19	-20	-20	N/A
12/31/2021	6	-17	-17	-17	N/A
9/30/2021	7	-18	N/A	N/A	N/A
6/30/2021	8	-18	-12	-12	N/A
3/31/2021	6	-17	-12	-12	N/A
12/31/2020	4	-16	-12	-12	N/A
9/30/2020	4	-14	N/A	N/A	N/A
6/30/2020	0	-10	-10	-10	N/A
3/31/2020	0	-10	-10	-10	N/A
12/31/2019	2	-10	-11	-10	N/A
9/30/2019	0	-9	N/A	N/A	N/A
6/30/2019	0	-10	-12	-12	N/A
3/31/2019	0	-11	-11	-11	N/A
12/31/2018	0	-12	-11	-11	N/A
9/30/2018	N/A	-12	N/A	N/A	N/A
6/30/2018	0	-12	-10	-10	N/A
3/31/2018	0	-10	-9	-9	N/A
12/31/2017	N/A	-9	-8	-8	N/A
9/30/2017	N/A	-8	N/A	N/A	N/A
6/30/2017	N/A	-7	N/A	-6	N/A
3/31/2017	N/A	-6	N/A	-6	N/A
12/31/2016	N/A	-5	N/A	-6	N/A
9/30/2016	0	-5	N/A	N/A	N/A
6/30/2016	0	-5	N/A	-5	N/A
3/31/2016	0	-4	N/A	-4	N/A
12/31/2015	0	-4	N/A	-3	N/A
9/30/2015	0	-3	N/A	N/A	N/A
6/30/2015	0	-3	N/A	-3	N/A
3/31/2015	0	-2	N/A	-3	N/A
12/31/2014	0	-2	N/A	-3	N/A
9/30/2014	0	-2	N/A	N/A	N/A
6/30/2014	0	-2	N/A	N/A	N/A
3/31/2014	0	-2	N/A	N/A	N/A
12/31/2013	0	-2	N/A	-1	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ALQGCの予測収益成長が貯蓄率 ( 1.1% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: ALQGCの収益がFrench市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: ALQGCの収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: ALQGCの収益がFrench市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: ALQGC来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ALQGCの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Quantum Genomics Société Anonyme 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

No longer forecast to breakeven

Consensus EPS estimates fall from profit to €0.33 loss

Forecast breakeven date pushed back to 2024

Price target decreased to €9.76

Forecast breakeven date pushed back to 2023

Forecast breakeven date pushed back to 2023

Recent updates

New major risk - Shareholder dilution

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

New major risk - Financial position

No longer forecast to breakeven

New major risk - Share price stability

Full year 2022 earnings: Revenues miss analyst expectations

Consensus EPS estimates fall from profit to €0.33 loss

Forecast breakeven date pushed back to 2024

Less than half of directors are independent

Price target decreased to €9.76

Quantum Genomics Announces Lack of Significant Efficacy for Firibastat in Their Phase III Study, Fresh and Is Redirecting to New Developments

Forecast breakeven date pushed back to 2023

First half 2022 earnings released: EPS: €0 (vs €0.23 loss in 1H 2021)

Forecast breakeven date pushed back to 2023

Consensus forecasts updated

Quantum Genomics Announces the Appointment of Its New Scientific Advisory Board

Quantum Genomics Announces the End of Patient Recruitment for its Phase III Pivotal Study FRESH

Quantum Genomics Appoints Sarah Merlen Boulenger as Head of Regulatory Affairs

Consensus forecasts updated

No independent directors

Quantum Genomics Announces Publication of a New Scientific Article Featuring QGC606

Quantum Genomics Announces Granting of New Patents Protecting QGC606

Quantum Genomics Société Anonyme announced that it expects to receive $2 million in funding from Gulf Pharmaceutical Industries P.S.C.

No longer forecast to breakeven

Quantum Genomics Presents Results from Phase IIb QUORUM Study of Firibastat

Quantum Genomics Société Anonyme announced that it has received €0.87 million in funding from Orient EuroPharma Co., Ltd.

Quantum Genomics Launches Phase III Pivotal REFRESH Study in Difficult-to-treat/Resistant Hypertension with Once-a-day Formulation of Firibastat

New 90-day high: €5.54

Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Faran

Quantum Genomics Signs Strategic Contract with Delpharm

Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with DongWha Pharm

New 90-day high: €4.07

Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Xediton Pharmaceuticals

Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Qilu Pharmaceutical to Develop and Commercialize Firibastat in Greater China Region, Hong Kong and Macao

New 90-day high: €3.14

Analysts update estimates

Quantum Genomics Société Anonyme Announces Resignation of Jean-Paul Kress from the Board

Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Orient EuroPharma (OEP)

New 90-day low: €2.28

New 90-day low - €2.51

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘